Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03405610 · ClinicalTrials.gov registry record · NA

A Skills-Based Program Delivered Via Secure Live Video to Patients With Acute Musculoskeletal Trauma

A NA study of Musculoskeletal Injury and Fracture, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT03405610: Completed NA study of Musculoskeletal Injury and Fracture, sponsored by Massachusetts General Hospital.

NCT03405610 is a NA study of Musculoskeletal Injury and Fracture that has completed, run by Massachusetts General Hospital. The registered enrollment target is 55 participants, below the 518-participant average among 15 other Musculoskeletal Injury trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03405610, a NA study of Musculoskeletal Injury and Fracture, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

The aims of this study are to test a manualized mind body skills-building program aimed at preventing the development of chronic pain and disability following acute musculoskeletal injury in at-risk patients.

Primary Outcome

We will report number of patients approached, number who agreed to participate/were screened, number of patients randomized

Interventions

  • BEHAVIORAL The Toolkit for Optimal Recovery after Injury

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2015-07-01
Est. Completion 2018-08-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT03405610 record still lists

NCT03405610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 518-participant average among 15 other Musculoskeletal Injury trials with a reported enrollment target (89% lower).

The record links to 2 conditions, with Musculoskeletal Injury appearing as the primary indexed condition, and to 1 intervention - of which The Toolkit for Optimal Recovery after Injury is the first listed.

NCT03405610 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03405610 about?

NCT03405610 is a clinical study titled "A Skills-Based Program Delivered Via Secure Live Video to Patients With Acute Musculoskeletal Trauma". The aims of this study are to test a manualized mind body skills-building program aimed at preventing the development of chronic pain and disability following acute musculoskeletal injury in at-risk patients.

What is the current status of trial NCT03405610?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2015-07-01. Estimated completion is 2018-08-01.

What conditions does trial NCT03405610 study?

This clinical trial studies the following conditions: Musculoskeletal Injury, Fracture.

What interventions are being tested in trial NCT03405610?

The interventions under investigation include: The Toolkit for Optimal Recovery after Injury (BEHAVIORAL).

Who is sponsoring clinical trial NCT03405610?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03405610 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Musculoskeletal Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03405610's enrollment target sits among peer trials

55 11th of 15 higher than 5 of 15 other Musculoskeletal Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Musculoskeletal Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03405610, the US trial registry maintained by the National Library of Medicine. NCT03405610 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.